Biology subjects

Ghasemizadeh, A.

Publications and source records attributed to Ghasemizadeh, A..

4 recordsLinked to original sources

bioRxiv2025

Multivalent Lipid MVL5 Micellar Nanoparticles Exhibit Dramatically Increased Loading of Paclitaxel with PEGylation Enhancing Human Cancer Cell Penetration Depth and Cytotoxicity

Cationic liposomes (CLs) with chain-melted fluid membranes are promising nanocarriers of hydrophobic drugs in cancer chemotherapy, including the frequently employed drug paclitaxel (PTX). CL formulations containing univalent N-[2,3-dioleoyloxy-1-propyl]trimethylammonium chloride (DOTAP), like EndoTAG-1TM, have shown limited success in clinical trials and challenges like endosomal entrapment, limited PTX membrane solubility, and difficulty with in vivo tumor targeting remain. Incorporation of 10 mol% cone-shaped poly(ethylene glycol)-lipid (PEG-lipid) to DOTAP-containing CLs transitions a fraction of the particles to micellar nanodiscs. These PTX--loaded PEGylated CLs and nanodiscs show enhanced cellular uptake in vitro and improved tumor penetration and proapoptotic activity compared to bare CLs in an in vivo solid breast cancer tumor model. Formulations incorporating the multivalent cationic lipid MVL5 (+5e) at 50 mol% form nanoparticles (NPs) comprised almost entirely of nanodiscs, and transition at 75 mol% MVL5 to short micellar rods coexisting with spheres, with rods further transitioning to long flexible rods upon PEGylation. Here, we report on the finding that MVL5-based micellar NPs with disc, rod, and spherical morphologies dramatically improve the solubility of PTX in their fluid lipid membranes by nearly three-fold compared to reference CLs modeled on the EndoTAG-1TM formulation. Cell viability assays revealed that this improved PTX solubility for MVL5 micellar NPs leads to improved cytotoxic efficacy, which is further improved by PEGylation. Remarkably, using fluorescent microscopy and image particle analysis, we find that the cellular uptake and penetration depth of MVL5 nanoparticles is significantly improved by PEGylation. The findings are consistent with a model where the rate-limiting step of PTX delivery by cationic lipid NPs is diffusion of endocytic vesicles containing NPs through the actin mesh near the cell surface combined with the hoping rate of PTX from endosomal membrane to nearby microtubules. PEGylated cationic lipid nanoparticles containing MVL5 therefore represent a very promising hydrophobic cancer drug delivery vehicle for nanomedicine applications.

bioengineering↗

bioRxiv2024

A Library of Custom PEG-Lipids reveals a Double-PEG-Lipid with Drastically Enhanced Paclitaxel Solubility and Human Cancer Cell Cytotoxicity when used in Fluid Micellar Nanoparticles

Paclitaxel (PTX) is one of the most widely utilized chemotherapeutics globally. However, the extremely poor water solubility of paclitaxel necessitates a mechanism of delivery within blood. Fluid lipid PTX nanocarriers (lipids in the chain-melted state) show promise as PTX delivery vectors, but remain limited by their solubility of PTX within the membrane. To improve pharmacokinetics, membrane surfaces are typically coated with polyethylene glycol (PEG). Recent work has demonstrated the generation of a population of micelles within fluid lipid formulations containing a 2kDa PEG-lipid at a 10 mol% ratio. Driven by the positive curvature of the PEG-lipid (i.e. area of head group > area of tails), micelle-containing formulations were found to exhibit significantly higher uptake in cancer cells, cytotoxicity, and in vivo antitumor efficacy compared to formulations containing solely liposomes. Here, we describe the custom synthesis of a library of high-curvature micelle-inducing PEG-lipids and examine the effects of PEG chain length, chain branching (single- or double-PEG-lipid), and cationic charge on PTX solubility and cytotoxicity. We examined PEG-lipids at standard (10 mol%) and high (100-x mol%, where x=PTX mol%) formulation ratios. Remarkably, all formulations containing the synthesized high-curvature PEG-lipids had improved PTX solubility over unPEGylated formulations and commercially available DOPE-5k. The highest PTX solubility was found within the 100-xO_SCPLOWPTXC_SCPLOW mol% PEG-lipid micellar formulations, with particles made from 2k2 (two PEG2k chains) encapsulating 13 mol% PTX for up to 24 h. The pancreatic cancer cell line PC3 exhibited higher sensitivity to formulations containing PEG-lipid at 100-xO_SCPLOWPTXC_SCPLOW mol%, the most potent of which being formulations made from 2k2 (IC50 = 14 nM). The work presented here suggests formulations employing high-curvature PEG-lipids, particularly the double-PEG-lipid 2k2, hold great potential as next-generation PTX delivery systems owing to their high PTX solubility, enhanced cell cytotoxicity, and ability for precision targeting by affixation of ligands to the PEG molecules.

bioengineering↗

bioRxiv2020

SH3KBP1 scaffolds endoplasmic reticulum and controls skeletal myofibers architecture and integrity

The building block of skeletal muscle is the multinucleated muscle fiber, formed by the fusion of hundreds of mononucleated precursor cells, myoblasts. In the normal course of muscle fiber development or regeneration, myonuclei are actively positioned throughout muscular development and adopt special localization in mature fibers: regular spacing along muscle fibers periphery, raising the notion of MyoNuclear Domains (MNDs). There is now growing support for a direct connection between myonuclear positioning and normal function of muscles, but how myonuclei affects muscle function remains poorly characterized. To identify new factors regulating forces applied on myonuclei in muscles fibers, we performed a siRNA screen and identified SH3KBP1 as a new factor controlling myonuclear positioning in early phases of myofibers formation. Depletion of SH3KBP1 induces a reset of MNDs establishment in mature fibers reflected by a dramatic reduction in pairwise distance between myonuclei. We show that SH3KBP1 scaffolds Endoplasmic Reticulum (ER) in myotubes that in turn controls myonuclei velocity and localization and thus myonuclear domains settings. Additionally, we show that in later phases of muscle maturation, SH3KBP1 contributes to the formation and maintenance of Sarcoplasmic Reticulum (SR) and Transverse-tubules (T-tubules). We also demonstrate that in muscle fibers, GTPase dynamin-2 (DNM2) binds to SH3 domains of SH3KBP1. Interestingly, we observed that Sh3kbp1 mRNA is up regulated in a mouse model harboring the most frequent mutation for Autosomal Dominant CentroNuclear Myopathy (AD-CNM): Dnm2+/R465W. SH3KBP1 thus appears as a compensation mechanism in this CNM model since its depletion contributes to an increase of CNM-like phenotypes (reduction of muscle fibers Cross-section Areas (CSA) and increase in slow fibers content). Altogether our results identify SH3KBP1 as a new regulator of myonuclear domains establishment in the early phase of muscle fibers formation through ER scaffolding and later in myofibers integrity through T-tubules scaffolding/maintenance. SummaryMyonuclei are actively positioned throughout muscular development. Guiraud, Christin, Couturier et al show that SH3KBP1 scaffolds the ER through Calnexin interaction and controls myonuclei motion during early steps of muscle fibers formation. Besides SH3KBP1 participates in cell fusion and T-tubules formation/maintenance in mature skeletal muscle fibers and contributes to slow-down CNM-like phenotypes.

cell biology↗

bioRxiv2019

Muscle MACF1 maintains myonuclei and mitochondria localization through microtubules to control muscle functionalities

Skeletal muscle is made from multinuclear myofiber, where myonuclei are positioned at the periphery or clustered below neuromuscular junctions (NMJs). While mispositioned myonuclei are the hallmark of numerous muscular diseases, the molecular machinery maintaining myonuclei positioning in mature muscle is still unknown. Here, we identified microtubule-associated protein MACF1 as an evolutionary conserved regulator of myonuclei positioning, in vitro and in vivo, controlling the \"microtubule code\" and stabilizing the microtubule dynamics during myofibers maturation, preferentially at NMJs. Specifically, MACF1 governs myonuclei motion, mitochondria positioning and structure and acetylcholine receptors (AChRs) clustering. Macf1-KO in young and adult mice decreases muscle excitability and causes evolutionary myonuclei positioning alterations in adult mice, paralleled with high mitochondria content and improved resistance to fatigue. We present MACF1 as a primary actor of the maintenance of synaptic myonuclei and AChRs clustering, peripheral myonuclei positioning and mitochondria organization through the control of microtubule network dynamics in muscle fibers.

cell biology↗